Endocannabinoids control spasticity in a multiple sclerosis model.
Spasticity is a complicating sign in multiple sclerosis that also develops in a model of chronic relapsing experimental autoimmune encephalomyelitis (CREAE) in mice. In areas associated with nerve damage, increased levels of the endocannabinoids, anandamide (arachidonoylethanolamide, AEA) and 2-arac...
Main Authors: | Baker, D, Pryce, G, Croxford, J, Brown, P, Pertwee, R, Makriyannis, A, Khanolkar, A, Layward, L, Fezza, F, Bisogno, T, Di Marzo, V |
---|---|
Format: | Journal article |
Language: | English |
Published: |
2001
|
Similar Items
-
Cannabinoids control spasticity and tremor in a multiple sclerosis model.
by: Baker, D, et al.
Published: (2000) -
Endocannabinoid Signaling Regulates Sleep Stability.
by: Matthew J Pava, et al.
Published: (2016-01-01) -
Arvanil-induced inhibition of spasticity and persistent pain: evidence for therapeutic sites of action different from the vanilloid VR1 receptor and cannabinoid CB(1)/CB(2) receptors.
by: Brooks, J, et al.
Published: (2002) -
Clinical insights on the spasticity-plus syndrome in multiple sclerosis
by: Kanza Alami Marrouni, et al.
Published: (2022-08-01) -
A evaluation of the shift in spasticity category in individuals with multiple sclerosis-related spasticity treated with nabiximols
by: Clara Grazia Chisari, et al.
Published: (2023-09-01)